Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo

Canadian Journal of Physiology and Pharmacology

Volumn 92, Issue 11, 2014, Pages 927-935

  Zhu, Wenhe ^a   Wang, Changwen ^a   Liu, Lei ^a   Li, Yan ^a   Li, Xiaokun ^b   Cai, Jianhui ^a   Wang, Huiyan ^a  

^a JILIN MEDICAL COLLEGE   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; FGF 21; HUVECs; Oxidative stress

Indexed keywords

CASPASE 3; FIBROBLAST GROWTH FACTOR 21; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROGEN PEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; SIMVASTATIN; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; APOPTOSIS REGULATORY PROTEIN; FIBROBLAST GROWTH FACTOR; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CELL CULTURE; CELL DAMAGE; CELL STRUCTURE; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; ESCHERICHIA COLI; FOAM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LIPID METABOLISM; MALE; NONHUMAN; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ATHEROSCLEROSIS; CELL SURVIVAL; DNA FRAGMENTATION; FIBROBLAST GROWTH FACTORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROGEN PEROXIDE; MALE; MAP KINASE SIGNALING SYSTEM; OXIDATIVE STRESS; RATS, WISTAR; RECOMBINANT PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84909958074     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2014-0227     Document Type: Article

References (32)

1. Amira, O.C., Naicker, S., Manga, P., Sliwa, K., Mia, A., Raal, F., et al. 2012. Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease. Hemodial. Int. 16(1): 59-68. doi:10.1111/j.1542-4758.2011.00622.x. PMID:22099423.
2. Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., and Maratos-Flier, E. 2007. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5(6): 426-437. doi:10.1016/j.cmet.2007.05.002. PMID: 17550778.
3. Berglund, E.D., Li, C.Y., Bina, H.A., Lynes, S.E., Michael, M.D., Shanafelt, A.B., et al. 2009. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology, 150(9): 4084-4093. doi:10.1210/en.2009-0221. PMID:19470704.
4. Christodoulides, C., Lagathu, C., Sethi, J.K., and Vidal-Puig, A. 2009. Adipogenesis and WNT signalling. Trends Endocrinol. Metab. 20(1): 16-24. doi:10.1016/j.tem.2008.09.002. PMID:19008118.
5. Coskun, T., Bina, H.A., Schneider, M.A., Dunbar, J.D., Hu, C.C., Chen, Y., et al. 2008. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology, 149(12): 6018-6027. doi:10.1210/en.2008-0816. PMID:18687777.
6. Crosby, J.R., Kaminski, W.E., Schatteman, G., Martin, P.J., Raines, E.W., Seifert, R.A., and Bowen-Pope, D.F. 2000. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ. Res. 87(9): 728-730. doi:10.1161/01.RES.87.9.728. PMID:11055974.
7. Guevara, N.V., Chen, K.H., and Chan, L. 2001. Apoptosis in atherosclerosis: pathological and pharmacological implications. Pharmacol. Res. 44(2): 59-71. doi: 10.1006/phrs.2001.0840. PMID:11516253.
8. Hotta, Y., Nakamura, H., Konishi, M., Murata, Y., Takagi, H., Matsumura, S., et al. 2009. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology, 150(10): 4625-4633. doi:10.1210/en.2009-0119. PMID:19589869.
9. Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., et al. 2007. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5(6): 415-425. doi:10.1016/j. cmet.2007.05.003. PMID:17550777.
10. Inoue, S., Browne, G., Melino, G., and Cohen, G.M. 2009. Ordering of caspases in cells undergoing apoptosis by the intrinsic pathway. Cell Death Differ. 16(7): 1053-1061. doi:10.1038/cdd.2009.29. PMID:19325570.
11. Izumiya, Y., Bina, H.A., Ouchi, N., Akasaki, Y., Kharitonenkov, A., and Walsh, K. 2008. FGF21 is an Akt-regulated myokine. FEBS Lett. 582(27): 3805-3810.doi: 10.1016/j.febslet.2008.10.021. PMID:18948104.
12. Kharitonenkov, A., and Larsen, P. 2011. FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol. Metab. 22(3): 81-86. doi:10.1016/j.tem.2010.11.003. PMID:21194964.
13. Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., et al. 2005. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115(6): 1627-1635. doi:10.1172/JCI23606. PMID:15902306.
14. Kharitonenkov, A., Wroblewski, V.J., Koester, A., Chen, Y.F., Clutinger, C.K., Tigno, X.T., et al. 2007. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 148(2): 774-781. doi:10.1210/en. 2006-1168. PMID:17068132.
15. Kharitonenkov, A., Beals, J.M., Micanovic, R., Strifler, B.A., Rathnachalam, R., et al. 2013. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One, 8(3): e58575. doi:10.1371/journal.pone.0058575. PMID:23536797.
16. Kiel, C., and Serrano, L. 2012. Challenges ahead in signal transduction: MAPK as an example. Curr. Opin. Biotechnol. 23(3): 305-314. doi:10.1016/j.copbio.2011.10.004. PMID:22036710.
17. Lee, J.S., Jung, W.K., Jeong, M.H., Yoon, T.R., and Kim, H.K. 2012. Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway. Int. J. Toxicol. 31(1): 70-77. doi:10.1177/1091581811423845. PMID:22215411.
18. Liu, X., Chen, Y., Wu, X., Li, H., Jiang, C., Tian, H., et al. 2012. SUMO fusion system facilitates soluble expression and high production of bioactive human fibroblast growth factor 23 (FGF23). Appl. Microbiol. Biotechnol. 96(1): 103-111. doi:10.1007/s00253-011-3864-4. PMID:22249722.
19. Mizuguchi, Y., Oishi, Y., Miyoshi, H., Iuchi, A., Nagase, N., and Oki, T. 2008. Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circ. J. 72(4): 538-544. doi: 10.1253/circj.72.538. PMID:18362422.
20. Muise, E.S., Azzolina, B., Kuo, D.W., El-Sherbeini, M., Tan, Y., Yuan, X., et al. 2008. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol. Pharmacol. 74(2): 403-412. doi:10.1124/mol.108.044826. PMID:18467542.
21. Nishimura, T., Nakatake, Y., Konishi, M., and Itoh, N. 2000. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta, 1492(1): 203-206. doi:10.1016/S0167-4781(00)00067-1. PMID:10858549.
22. Olson, E.S., Whitney, M.A., Friedman, B., Aguilera, T.A., Crisp, J.L., Baik, F.M., et al. 2012. In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integr. Biol. 4(6): 595-605. doi:10.1039/c2ib00161f. PMID:22534729.
23. Ozcan, L. 2012. Endoplasmic reticulum stress in cardiometabolic disorders. Curr. Atheroscler. Rep. 14(5): 469-475. doi:10.1007/s11883-012-0270-z. PMID: 22847769.
24. Qiang, L., and Accili, D. 2012. FGF21 and the second coming of PPARgamma. Cell, 148(3): 397-398. doi:10.1016/j.cell.2012.01.020. PMID:22304910.
25. Shu, X., Wu, W., Mosteller, R.D., and Broek, D. 2002. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of Ras and mitogen-activated protein kinases. Mol. Cell. Biol. 22(22): 7758-7768. doi:10.1128/MCB.22.22.7758-7768.2002. PMID:12391145.
26. Singh, S. 2008. Scaling up anti-mycobacterial drug susceptibility testing services in India: it is high time. Indian J. Med. Microbiol. 26(3): 209-211. doi:10.4103/0255-0857.42029. PMID:18695315.
27. Sun, H.Y., Wang, N.P., Halkos, M., Kerendi, F., Kin, H., Guyton, R.A., et al. 2006. Postconditioning attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways. Apoptosis, 11(9): 1583-1593. doi:10.1007/s10495-006-9037-8. PMID:16820962.
28. Suzuki, M., Uehara, Y., Motomura-Matsuzaka, K., Oki, J., Koyama, Y., Kimura, M., et al. 2008. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22(4): 1006-1014. doi:10.1210/me.2007-0313. PMID:18187602.
29. Tan, S.M., Sharma, A., Yuen, D.Y., Stefanovic, N., Krippner, G., Mugesh, G., et al. 2013. The modified selenenyl amide, M-hydroxy ebselen, attenuates diabetic nephropathy and diabetes-associated atherosclerosis in ApoE/GPx1 double knockout mice. PLoS One, 8(7): e69193. doi:10.1371/journal.pone.0069193. PMID:23874911.
30. Veniant, M.M., Komorowski, R., Chen, P., Stanislaus, S., Winters, K., Hager, T., et al. 2012. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese Rhesus monkeys. Endocrinology, 153(9): 4192-4203. doi: 10.1210/en.2012-1211. PMID:22798348.
31. Wang, H., Xiao, Y., Fu, L., Zhao, H., Zhang, Y., Wan, X., et al. 2010.High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. BMC Biotechnol. 10: 14. doi:10.1186/1472-6750-10-14. PMID:20163718.
32. Zhang, M., Jiang, X., Su, Z., Lin, J., Xiang, Q., Yang, Z., et al. 2012. Large-scale expression, purification, and glucose uptake activity of recombinant human FGF21 in Escherichia coli. Appl. Microbiol. Biotechnol. 93(2): 613-621. doi:10.1007/s00253-011-3427-8. PMID:21713513.